The goal of this study is to assess the long-term safety, efficacy and performance of VenusP-Valve™ implantation. in all subjects who provided informed consent and received VenusP-Valve™ implantation in the VenusP-Valve™ system CE registration study (Protocol ID Number: VMT-001CE; NCT02846753). Annual clinic visits will be conducted from year 6 through year 10 post-implantation, including transthoracic echocardiography, New York Heart Association (NYHA) functional classification assessment, adverse event evaluation, and review of cardiovascular medication use at each visit..
Study Type
OBSERVATIONAL
Enrollment
55
Right ventricular reverse remodeling and improvement rate of right ventricular function were followed up at 6 months after operation
The right ventricular reverse remodeling and the improvement rate of right ventricular function at 6 months after operation were defined as the 6-month follow-up The right ventricular end-diastolic volume index measured by CMR was within the normal range, that is, RVEDVI≤108mL/m2.
Time frame: From enrollment to month-6 post procedure.
adverse events and moderate or greater pulmonary regurgitation at 6 years, 7 years, 8 years, 9 years and 10 years.
1. Occurrence of the following adverse events at 6 years, 7 years, 8 years, 9 years and 10 years: * Device migration/embolization * Valvar thrombosis * Thromboembolism * Bleeding * Paravalvular leak * Endocarditis * Nonstructural dysfunction * Explant * Hemolysis * Arrhythmias 2. Moderate or greater pulmonary regurgitation by echocardiography at 6 years, 7 years, 8 years, 9 years and 10 years.
Time frame: From enrollment to 10 years post procedure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.